Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-α in patients with coronary heart disease

Clinical Science

Volumn 110, Issue 3, 2006, Pages 353-360

  Robinson, Simon D ^a   Dawson, Pamela ^b   Ludlam, Christopher A ^b   Boon, Nicholas A ^b   Newby, David E ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Coronary disease; Endothelial function; Fibrinolysis; Inflammation; Tumour necrosis factor (TNF ); Vasodilation

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANGINA PECTORIS AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; STATINE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD FLOW; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIUM; FEMALE; FIBRINOLYSIS; FOREARM; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; VASCULAR DISEASE; VASODILATATION; VASOMOTOR REFLEX;

ACUTE DISEASE; ADULT; AGED; C-REACTIVE PROTEIN; CORONARY DISEASE; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; FOREARM; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS; VASODILATION; VASOMOTOR SYSTEM;

EID: 33644786967     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050268     Document Type: Article

References (32)

1. Thompson, S. G., Kienast, J., Pyke, S. D., Haverkate, F. and van de Loo, J. C. (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332, 635-641
2. Ridker, P. M., Vaughan, D. E., Stampfer, M. J., Manson, J. E. and Hennekens, C. H. (1993) Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341, 1165-1168
3. Mann, J. and Davies, M. J. (1999) Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 82, 265-268
4. Haverkate, F., Thompson, S. G., Pyke, S. D., Gallimore, J. R. and Pepys, M. B. (1997) Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349, 462-466
5. Ridker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S. and Braunwald, E. (2000) Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149-2153
6. Haverkate, F., Thompson, S. G. and Duckert, F. (1995) Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb. Haemostasis 73, 561-567
7. Lowe, G. D., Danesh, J., Lewington, S. et al. (2004) Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis. Eur. Heart J. 25, 252-259
8. Ludmer, P. L., Selwyn, A. P., Shook, T. L. et al. (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315, 1046-1051
9. Hingorani, A. D., Cross, J., Kharbanda, R. K. et al. (2000) Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102, 994-999
10. Chia, S., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2003) Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. J. Am. Coll. Cardiol. 41, 333-339
11. Fichtlscherer, S., Rosenberger, G., Walter, D. H., Breuer, S., Dimmeler, S. and Zeiher, A. M. (2000) Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102, 1000-1006
12. Speidl, W. S., Zeiner, A., Nikfardjam, M. et al. (2005) An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll. Cardiol. 45, 30-34
13. Chia, S., Qadan, M., Newton, R., Ludlam, C. A., Fox, K. A. and Newby, D. E. (2003) Intra-arterial tumor necrosis factor-α impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler., Thromb., Vasc. Biol. 23, 695-701
14. Newby, D. E., Wright, R. A., Labinjoh, C. et al. (1999) Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99, 1411-1415
15. Paramo, J. A., Orbe, J., Beloqui, O. et al. (2004) Prothrombin fragment 1 + 2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 35, 1085-1089
16. Newby, D. E., Wright, R. A., Ludlam, C. A., Fox, K. A., Boon, N. A. and Webb, D. J. (1997) An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb. Haemostasis 78, 1242-1248
17. Biasucci, L. M., Vitelli, A., Liuzzo, G. et al. (1996) Elevated levels of interleukin-6 in unstable angina. Circulation 94, 874-877
18. Lupu, F., Heim, D. A., Bachmann, F., Hurni, M., Kakkar, V. V. and Kruithof, E. K. O. (1995) Plasminogen activator expression m human atherosclerotic lesions. Arterioscler., Thromb., Vasc. Biol. 15, 1444-1455
19. Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, Jr, D. R. and Lerman, A. (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954
20. Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T. and Munzel, T. (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104, 2673-2678
21. Yki-Jarvinen, H., Bergholm, R. and Leirisalo-Repo, M. (2003) Increased inflammatory activity parallels increased basal nitric oxide production and blunted response to nitric oxide in vivo in rheumatoid arthritis. Ann. Rheum. Dis. 62, 630-634
22. Fichtlscherer, S., Breuer, S., Schachinger, V., Dimmeler, S. and Zeiher, A. M. (2004) C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur. Heart J. 25, 1412-1418
23. Yoshizumi, M., Perrella, M. A., Burnett, Jr, J. C. and Lee, M. E. (1993) Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 73, 205-209
24. Boger, R. H., Bode-Boger, S. M., Szuba, A. et al. (1998) Asymmetric Dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842-1847
25. Funakoshi, H., Kubota, T., Machida, Y. et al. (2002) Involvement of mducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-α. Am. J. Physiol. Heart Circ. Physiol. 282, H2159-H2166
26. G-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br. J. Clin. Pharmacol. 38, 311-315
27. Honing, M. L. H., Smits, P., Morrison, P.J. and Rabelink, T. J. (2000) Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization. Hypertension 35, 1314-1318
28. Brown, N. J., Gainer, J. V., Murphey, L. J. and Vaughan, D. E. (2000) Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-mdependent pathway. Circulation 102, 2190-2196
29. Panza, J. A., Garcia, C. E., Kilcoyne, C. M., Quyyumi, A. A. and Cannon, R. O. (1995) Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91, 1732-1738
30. Steins, M. B., Padro, T., Li, C.-X. et al. (1999) Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries. Atherosclerosis 145, 173-180
31. Fichtlscherer, S., Rossig, L., Breuer, S., Vasa, M., Dimmeler, S. and Zeiher, A. M. (2001) Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104, 3023-3025
32. Mann, D. L., McMurray, J. J. V., Packer, M. et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomised Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594-1602